Zize Feng1, Dongsheng He, Zhigang Mao, Zongming Wang, Yonghong Zhu, Xiangsong Zhang, Haijun Wang. 1. From the Departments of *Neurosurgery and Pituitary Tumor Center, and ‡Nuclear Medicine, The First Affiliated Hospital; and †Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Abstract
PURPOSE: MRI is commonly used in the evaluation of pituitary adenomas (PAs). However, it has difficulty to locate the lesions sometimes, especially microadenomas and/or postoperative recurrent tumors. We aimed to evaluate the role of combined C-methionine (MET) and F-FDG PET/CT in patients with functioning PAs. PATIENTS AND METHODS: This study included 43 patients: 15 had Cushing disease, 16 had acromegaly, and 12 had a prolactinoma. F-FDG PET/CT was performed on all of the patients; C-MET PET/CT was performed on 39 of the patients. The PET images and surgical findings were analyzed. RESULTS: On F-FDG PET/CT, 29 (67%) of 43 cases had positive results, all of which were true positives, including 2 cases with equivocal MRI results. On C-MET PET/CT, 37 (95%) of 39 cases had positive results, of which 2 were false positives. All patients underwent surgery, and the results of PET/CT scans were confirmed by surgery and pathological examination. All F-FDG PET/CT results were negative when C-MET PET/CT results were negative. However, 12 patients with positive C-MET PET/CT results had negative F-FDG PET/CT results. The positive rate of F-FDG PET/CT in patients with somatostatin analog treatment, radiosurgery, transsphenoidal surgery, and microadenoma was 63% (5/8), 50% (1/2), 33% (4/12), and 48%(10/21), respectively, while that of C-MET PET/CT was 86% (6/7), 50% (1/2), 100% (12/12), and 100% (21/21), respectively. In the 9 patients with a recurrent microadenoma, the positive rate of F-FDG PET/CT was as low as 22% while that of C-MET PET/CT was 100%. There was no significant difference in the positive rate of C-MET and F-FDG PET/CT between the 3 types of PA. CONCLUSIONS: PET/CT may be useful to detect tumors in patients with equivocal MRI results. C-MET PET/CT can provide valuable diagnostic information when F-FDG PET/CT yields negative results, especially in patients with recurrent microadenomas.
PURPOSE: MRI is commonly used in the evaluation of pituitary adenomas (PAs). However, it has difficulty to locate the lesions sometimes, especially microadenomas and/or postoperative recurrent tumors. We aimed to evaluate the role of combined C-methionine (MET) and F-FDG PET/CT in patients with functioning PAs. PATIENTS AND METHODS: This study included 43 patients: 15 had Cushing disease, 16 had acromegaly, and 12 had a prolactinoma. F-FDG PET/CT was performed on all of the patients; C-MET PET/CT was performed on 39 of the patients. The PET images and surgical findings were analyzed. RESULTS: On F-FDG PET/CT, 29 (67%) of 43 cases had positive results, all of which were true positives, including 2 cases with equivocal MRI results. On C-MET PET/CT, 37 (95%) of 39 cases had positive results, of which 2 were false positives. All patients underwent surgery, and the results of PET/CT scans were confirmed by surgery and pathological examination. All F-FDG PET/CT results were negative when C-MET PET/CT results were negative. However, 12 patients with positive C-MET PET/CT results had negative F-FDG PET/CT results. The positive rate of F-FDG PET/CT in patients with somatostatin analog treatment, radiosurgery, transsphenoidal surgery, and microadenoma was 63% (5/8), 50% (1/2), 33% (4/12), and 48%(10/21), respectively, while that of C-MET PET/CT was 86% (6/7), 50% (1/2), 100% (12/12), and 100% (21/21), respectively. In the 9 patients with a recurrent microadenoma, the positive rate of F-FDG PET/CT was as low as 22% while that of C-MET PET/CT was 100%. There was no significant difference in the positive rate of C-MET and F-FDG PET/CT between the 3 types of PA. CONCLUSIONS: PET/CT may be useful to detect tumors in patients with equivocal MRI results. C-MET PET/CT can provide valuable diagnostic information when F-FDG PET/CT yields negative results, especially in patients with recurrent microadenomas.
Authors: W A Bashari; M van der Meulen; J MacFarlane; D Gillett; R Senanayake; L Serban; A S Powlson; A M Brooke; D J Scoffings; J Jones; D G O'Donovan; J Tysome; T Santarius; N Donnelly; I Boros; F Aigbirhio; S Jefferies; H K Cheow; I A Mendichovszky; A G Kolias; R Mannion; O Koulouri; M Gurnell Journal: Pituitary Date: 2022-05-24 Impact factor: 3.599
Authors: Leontine E H Bakker; Marco J T Verstegen; Wouter R van Furth; Lenka M Pereira Arias Bouda; Eidrees Ghariq; Berit M Verbist; Pieter J Schutte; Waiel A Bashari; Mark C Kruit; Alberto M Pereira; Mark Gurnell; Nienke R Biermasz Journal: Pituitary Date: 2022-05-26 Impact factor: 3.599